Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging results from first-in-human trial of HNSA-5487 Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s…